{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Borgenvik A"],"funding":["Vetenskapsrådet","Cancer Research UK","Action Medical Research","Svenska Läkaresällskapet","Barncancerfonden","Cancerfonden","Ragnar Söderbergs stiftelse","Science for Life Laboratory","Åke Wiberg Stiftelse","European Research Council","Worldwide Cancer Research","Medical Research Council","National Institute for Health Research (NIHR)","NCI NIH HHS"],"pagination":["4586-4603"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9755969"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["82(24)"],"pubmed_abstract":["Relapse is the leading cause of death in patients with medulloblastoma, the most common malignant pediatric brain tumor. A better understanding of the mechanisms underlying recurrence could lead to more effective therapies for targeting tumor relapses. Here, we observed that SOX9, a transcription factor and stem cell/glial fate marker, is limited to rare, quiescent cells in high-risk medulloblastoma with MYC amplification. In paired primary-recurrent patient samples, SOX9-positive cells accumulated in medulloblastoma relapses. SOX9 expression anti-correlated with MYC expression in murine and human medulloblastoma cells. However, SOX9-positive cells were plastic and could give rise to a MYC high state. To follow relapse at the single-cell level, an inducible dual Tet model of medulloblastom"],"journal":["Cancer research"],"pubmed_title":["Dormant SOX9-Positive Cells Facilitate MYC-Driven Recurrence of Medulloblastoma."],"pmcid":["PMC9755969"],"funding_grant_id":["23391","1796","640275","CL-2014-01-502","MR/V001647/1","P30 CA030199"],"pubmed_authors":["Bravo MB","Wenz AS","Wechsler-Reya RJ","Kalushkova A","Garancher A","Hill RM","Remke M","Cancer M","Giraud G","Zhao M","Borgenvik A","Sundstrom A","Clifford SC","Verbaan AD","Rusert JM","Chen X","Dang Y","Bolin S","Hutter S","Rahmanto AS","Taylor MD","Sattanino D","Richardson S","Olsen TK","Swartling FJ","Rosen G","Sangfelt O","Mainwaring OJ","Weishaupt H","Dubuc AM","Bergstrom T","Jernberg-Wiklund H","Schuller U","Fotaki G","Savov V","Holmberg KO"],"additional_accession":[]},"is_claimable":false,"name":"Dormant SOX9-Positive Cells Facilitate MYC-Driven Recurrence of Medulloblastoma.","description":"Relapse is the leading cause of death in patients with medulloblastoma, the most common malignant pediatric brain tumor. A better understanding of the mechanisms underlying recurrence could lead to more effective therapies for targeting tumor relapses. Here, we observed that SOX9, a transcription factor and stem cell/glial fate marker, is limited to rare, quiescent cells in high-risk medulloblastoma with MYC amplification. In paired primary-recurrent patient samples, SOX9-positive cells accumulated in medulloblastoma relapses. SOX9 expression anti-correlated with MYC expression in murine and human medulloblastoma cells. However, SOX9-positive cells were plastic and could give rise to a MYC high state. To follow relapse at the single-cell level, an inducible dual Tet model of medulloblastom","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Dec","modification":"2026-05-28T03:43:00.563Z","creation":"2025-04-04T20:22:20.404Z"},"accession":"S-EPMC9755969","cross_references":{"pubmed":["36219398"],"doi":["10.1158/0008-5472.CAN-22-2108"]}}